SOURCE: Corporate Profile LLC

Corporate Profile LLC

March 31, 2010 13:48 ET

Corporate Profile's CPreports.com Publishes Gene Marcial Investor Alert for Rexahn Pharmeceuticals

NEW YORK, NY--(Marketwire - March 31, 2010) - Corporate Profile's newest financial website, CPreports.com, announces an Investor Alert by Gene Marcial discussing Rexahn Pharmaceuticals (NYSE Amex: RNN). See full article at http://www.cpreports.com or http://www.cpreports.com/?p=78

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ -- all potential best in class therapeutics -- and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit http://www.rexahn.com.

About CPreports.com

CPReports.com features Gene Marcial's Inside Wall Street Newsletter, published three times a week exclusively on CPReports.com. The website and newsletter provide readers and subscribers fresh, original, and highly informative ideas and market commentary that they won't get anywhere else. Content is focused on what is going on in the stock market and on Wall Street, including stories about large-capitalization as well as small-cap companies, both on the long and short side.

About Corporate Profile.com

CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in the unique platform for today's hottest tips and market info.

Safe Harbor Disclaimer

Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.